Evidence map›Paper›PMID 37880912›Full record

ArticleCancer2024

Health care utilization by long-term survivors of blood or marrow transplantation-A Bone Marrow Transplant Survivor Study report.

Marian M Oliver, Qingrui Meng, Lindsey Hageman, Wendy Landier, Nora Balas, Elizabeth Ross, Liton Francisco, Alysia Bosworth, Hok Sreng Te, F Lennie Wong and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Marian M OliverInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0009-0000-7759-7763
Qingrui MengInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Lindsey HagemanInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Wendy LandierInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Nora BalasInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Elizabeth RossInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0003-1972-6015
Liton FranciscoInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Alysia BosworthDepartment of Population Sciences, Hematologic Malignancies Research Institute, Department of Pediatrics, City of Hope, Duarte, California, USA.ORCID 0000-0002-0662-5699
Hok Sreng TeDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
F Lennie WongDepartment of Population Sciences, Hematologic Malignancies Research Institute, Department of Pediatrics, City of Hope, Duarte, California, USA.
Ravi BhatiaInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Stephen J FormanDepartment of Population Sciences, Hematologic Malignancies Research Institute, Department of Pediatrics, City of Hope, Duarte, California, USA.
Saro H ArmenianDepartment of Population Sciences, Hematologic Malignancies Research Institute, Department of Pediatrics, City of Hope, Duarte, California, USA.ORCID 0000-0003-2604-8603
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, Division of Pediatric Hematology/Oncology, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-7755-5683
University of Alabama at Birmingham · USCity of Hope · USUniversity of Minnesota · US

Funding

BMT Survivor Study-2 (BMTSS-2)U01CA213140 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, SMITA · 2019 to 2023
$6.8M
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDYR01CA078938 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BHATIA, SMITA · 2000 to 2003
$1.6M
NCI NIH HHS R01 CA078938NCI NIH HHS U01 CA213140
6 · The paper itself

Abstract

backgroundBlood or marrow transplantation (BMT) survivors carry a high burden of morbidity, yet health care utilization by this vulnerable population remains understudied. Patterns and predictors of various domains of health care utilization in long-term BMT survivors were evaluated.

methodsStudy participants were drawn from the Bone Marrow Transplant Survivor Study (BMTSS). Patients transplanted between 1974 and 2014 at one of three transplant centers who had survived ≥2 years after BMT and were aged ≥18 years at the time of the study were included. A BMTSS survey served as the source of data for health care utilization, sociodemographics, and chronic health conditions. Domains of health care utilization in the 2 years preceding study participation included routine checkups, BMT-related visits, transplant/cancer center visits, emergency room (ER) visits, hospitalizations, and high health care utilization (≥7 physician visits during the 2 years before the study). Clinical characteristics and therapeutic exposures were abstracted from medical records.

resultsIn this cohort of 3342 BMT survivors (52% allogeneic), the prevalence of health care utilization declined over time since BMT for both allogeneic and autologous BMT survivors, such that among those who had survived ≥20 years, only 49%-53% had undergone routine checkups, 37%-38% reported BMT-related visits, and 28%-29% reported transplant/cancer center visits. The presence of severe/life-threatening conditions and chronic graft-vs-host disease increased the odds of health care utilization across all domains. Lower education, lack of insurance, and Hispanic ethnicity were associated with a lower prevalence of routine checkups and/or transplant/cancer center visits. Lower income increased the odds of ER visits but reduced the odds of hospitalizations or high health care utilization.

conclusionsThis study identified vulnerable populations of long-term BMT survivors who would benefit from specialized risk-based anticipatory care to reduce high health care utilization, ER visits, and hospitalizations.

Indexed as

Bone MarrowHematopoietic Stem Cell TransplantationAdolescentAdultBone Marrow TransplantationChronic DiseaseHumansPatient Acceptance of Health CareSurvivorsallogeneic or autologous transplantblood or marrow transplantationBMThealthcare utilizationlong-term survivorssurvivors

Identifiers

PMID37880912
PMCPMC10922070
OpenAlexW4387948638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.